Clinical trial
Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive…
NCT00303992 · University of California, San Francisco, Other · Completed
Key facts
| NCT number | NCT00303992 |
|---|---|
| Title | Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer |
| Official title | Weekly Trastuzumab (Herceptin) and Irinotecan in Patients With HER-2 Positive Advanced Breast Cancer: A Phase II Trial |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, irinotecan hydrochloride |
| Enrollment | 9 |
| Start date | May 1, 2004 |
| Primary completion | Nov 16, 2006 |
| Completion | Jan 1, 2013 |
| First posted | Mar 17, 2006 |
| Last update posted | Jan 17, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: